Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Associated Therapies: -

Clinical Trials

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: erlotinib

First Posted Date: 2010-10-08

Last Posted Date: 2017-09-12

Lead Sponsor: Baohui Han

Target Recruit Count: 25

Registration Number: NCT01217619

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions: Drug: U3-1287
Drug: Placebo
Drug: Erlotinib

First Posted Date: 2010-09-29

Last Posted Date: 2021-06-16

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 222

Registration Number: NCT01211483

Locations: 🇺🇸
TRM - Oncology Research Associates, PLLC, d/b/a Pinnacle Oncology Hematology, Scottsdale, Arizona, United States

Metformin Combined With Chemotherapy for Pancreatic Cancer

Phase 2

Completed

Conditions: Locally Advanced Pancreatic Cancer
Metastatic Pancreatic Cancer

Interventions: Drug: gemcitabine
Drug: erlotinib
Drug: placebo
Drug: metformin

First Posted Date: 2010-09-29

Last Posted Date: 2021-04-21

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 120

Registration Number: NCT01210911

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Netherlands

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Hormone-sensitive Metastatic Breast Cancer

Interventions: Drug: OSI-906
Drug: Erlotinib
Drug: Letrozole
Drug: Goserelin

First Posted Date: 2010-09-20

Last Posted Date: 2012-09-11

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 11

Registration Number: NCT01205685

Locations: 🇺🇸
Vanderbilt-Ingram Oncology Cool Springs, Franklin, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Vanderbilt One Hundre Oaks, Nashville, Tennessee, United States